What Clinical Metrics Determine if a Child Has Outgrown a Peanut Allergy?

Introduction

If your child was diagnosed with a peanut allergy in early life, you may have been told there is a possibility they could outgrow it as they get older. For many families, this raises an understandable and important question: how do doctors actually determine whether a child has developed tolerance to peanuts, and what does that process involve?

Peanut allergy is one of the most common food allergies in children in the UK, and unlike some other childhood food allergies — such as those to milk or egg — it has historically been considered less likely to resolve on its own. However, research does show that a meaningful proportion of children with peanut allergy do develop natural tolerance over time, and clinical assessment can help identify whether that may have occurred.

This article explains the clinical markers and assessment methods that healthcare professionals use when evaluating whether a child's peanut allergy may have changed, including the role of specific IgE blood testing, skin-prick testing, component-resolved diagnostics and supervised oral food challenges.

Can a child outgrow a peanut allergy, and how is this assessed?

Some children do develop natural tolerance to peanuts over time, though this is less common than with milk or egg allergy. Determining whether a child has outgrown a peanut allergy involves monitoring specific IgE blood levels, skin-prick test results and, where clinically appropriate, a supervised oral food challenge. This should always be assessed by an appropriately qualified healthcare professional.

Can Children Really Outgrow a Peanut Allergy?

Peanut allergy has traditionally been viewed as a lifelong condition for the majority of those affected. However, research — including data from UK and international allergy studies — suggests that approximately 20–25% of children with peanut allergy may develop tolerance during childhood or adolescence. This means that for a minority, the allergy does appear to resolve over time.

That said, outgrowing a peanut allergy is not something a family can or should attempt to determine at home. The process of assessing whether tolerance has developed requires structured clinical evaluation, as an incorrect assumption that a child has outgrown their allergy could lead to a potentially serious reaction.

It is also important to note that not every child with declining IgE levels has developed clinical tolerance, and not every child with persistent low IgE levels will react significantly to peanut exposure. This is why clinical assessment — rather than testing alone — is central to a responsible evaluation.

The Immunological Basis of Peanut Allergy

Peanut allergy is typically an IgE-mediated allergic response. When a child with peanut allergy is exposed to peanut proteins, their immune system produces allergen-specific immunoglobulin E (IgE) antibodies directed against components of the peanut. These IgE antibodies bind to mast cells and basophils throughout the body. On subsequent exposure, peanut proteins cross-link these IgE antibodies, triggering the release of histamine and other inflammatory mediators. This is what produces the symptoms associated with an allergic reaction — which may range from mild skin or oral symptoms to more significant systemic reactions.

Over time, in some children, this immune response changes. The immune system may gradually shift away from producing high levels of allergen-specific IgE, or the immune response may become more regulated. When this happens, the child may tolerate increasing amounts of peanut protein without experiencing symptoms — a state referred to as clinical tolerance or resolution.

Understanding peanut allergy at the component level has become increasingly useful in clinical assessment. Peanuts contain several distinct proteins, known as components, and some are more strongly associated with severe reactions than others. Component-resolved diagnostics (CRD) can provide more detailed information about which specific peanut proteins a child is sensitised to, which can help inform clinical risk assessment. For those interested in understanding how broader multi-allergen blood testing is used in food allergy assessment, information about comprehensive allergy blood testing panels may provide helpful background.

Clinical Metrics Used in Peanut Allergy Evaluation

When a healthcare professional assesses whether a child may have outgrown their peanut allergy, several clinical markers are typically considered together. No single result can make this determination in isolation.

Allergen-Specific IgE Blood Testing

Specific IgE blood testing measures the level of IgE antibodies directed against peanut proteins in the child's blood. The result is expressed in kilounits per litre (kU/L). In general terms, lower specific IgE levels may be associated with a greater likelihood of tolerance, while higher levels are associated with a greater likelihood of persistent allergy.

However, IgE levels alone do not confirm or exclude the presence of clinical allergy. A child with a relatively low specific IgE level may still react to peanut exposure, and a child with an elevated level may tolerate small amounts. This is why IgE results must always be interpreted alongside the child's clinical history and other findings.

Monitoring trends in specific IgE levels over time — rather than a single isolated result — can provide more useful information. A consistent downward trend in peanut-specific IgE over several years, particularly from early childhood, may be an indicator that tolerance is developing.

People considering what specific IgE blood testing involves and how results are used may find it helpful to read about food and inhalant allergy profile blood testing to better understand how this type of test works.

Skin-Prick Testing

Skin-prick testing (SPT) involves applying a small amount of peanut extract to the surface of the skin, usually on the forearm, and introducing it just beneath the surface using a lancet. The size of any resulting wheal (a small raised area of skin) is measured after approximately 15 minutes.

A wheal of 3mm or more above the negative control is generally considered a positive result. Smaller wheals or a downward trend in wheal size over successive assessments may suggest a reduction in sensitisation, though — as with IgE blood levels — this does not by itself confirm tolerance.

Nationally and internationally, clinicians use threshold values for both specific IgE levels and SPT wheal sizes to help guide decisions about when an oral food challenge may be appropriate, though these thresholds are used as guides and not as rigid diagnostic rules.

Component-Resolved Diagnostics for Peanut

Component-resolved diagnostics allow clinicians to look beyond total peanut-specific IgE and examine which individual peanut proteins a child is sensitised to. This can be particularly informative in peanut allergy assessment.

Key peanut components include:

Ara h 1, Ara h 2, Ara h 3 — storage proteins associated with persistent, potentially severe peanut allergy
Ara h 8 — a component cross-reactive with birch pollen, often associated with milder oral allergy-type symptoms rather than systemic reactions
Ara h 9 — a lipid transfer protein more commonly associated with allergy in some Mediterranean populations

Sensitisation to Ara h 2 in particular has been associated in research with higher clinical reactivity and persistent allergy. Children who show lower or declining Ara h 2 levels, or who test negative to the storage proteins while remaining sensitised only to Ara h 8, may have a different clinical risk profile. This information can help a healthcare professional make a more informed decision about whether proceeding to an oral food challenge is appropriate.

The Role of the Supervised Oral Food Challenge

The supervised oral food challenge (OFC) is widely considered the most direct method of determining whether a child can tolerate peanut in practice. It involves the gradual introduction of increasing amounts of peanut protein under direct clinical supervision, typically in a hospital or specialist allergy unit setting where trained staff and emergency medication are immediately available.

A negative OFC — meaning the child tolerates the target dose without experiencing a reaction — provides the most reliable evidence that clinical tolerance has been achieved.

An OFC is not appropriate in every situation. Clinicians take into account the child's recent clinical history, their current IgE and SPT findings, any recent reactions, and their overall health when deciding whether an OFC is safe and appropriate to proceed with. The OFC is not a test to be attempted at home under any circumstances.

What Does This Mean in Practice?

In practice, a child's peanut allergy is typically reviewed regularly — often annually in a specialist paediatric allergy setting — particularly if there is a clinical reason to suspect tolerance may be developing. Not every child with a peanut allergy will be offered annual testing or a food challenge, and the timing and approach will depend on the individual's clinical circumstances.

For families who have received allergy testing results and are uncertain about what they mean, it can be helpful to understand how allergy blood test pathways are typically structured before discussing them with a healthcare professional.

When Should You Speak to a Healthcare Professional?

You should seek appropriate clinical review if:

Your child was diagnosed with a peanut allergy and has not been reviewed by an appropriate healthcare professional for some time
Your child has experienced a reaction to peanut, or you are unsure whether they are avoiding peanut appropriately
You have been told or have read that your child's specific IgE levels have changed, and you would like clinical guidance on what this may mean
You are considering whether your child might now tolerate peanut and are unsure what steps to take

Do not attempt to introduce peanut at home without clinical guidance simply because specific IgE levels appear to have fallen. Any assessment of whether a peanut allergy has resolved should be done with appropriate medical oversight.

For children presenting with suspected or confirmed food allergy, a referral to a specialist paediatric allergy service via a GP remains an important route. Private allergy testing services can provide additional diagnostic information, but they complement — rather than replace — appropriate clinical assessment and should be interpreted with professional support.

For those exploring what a food allergy assessment may involve, information about common food and environmental allergen categories can provide useful background reading.

Key Points to Remember

Some children do develop natural tolerance to peanuts over time, but this is not the case for the majority, and the pattern varies from child to child.
Determining whether a peanut allergy has resolved involves a combination of clinical markers — including specific IgE levels, skin-prick test results, component-resolved diagnostics and clinical history — not a single test result.
Component-resolved diagnostics can provide additional information about which peanut proteins a child is sensitised to and what this may mean clinically.
The supervised oral food challenge is the most direct method of establishing clinical tolerance, but it must take place in an appropriate clinical setting.
A falling specific IgE level does not by itself confirm that a child has outgrown their peanut allergy.
Any reassessment of a child's peanut allergy should be carried out under appropriate clinical supervision — do not attempt unsupervised peanut introduction at home.

Frequently Asked Questions

At what age do children most commonly outgrow a peanut allergy?

Research suggests that natural tolerance to peanut, when it does develop, most often occurs during childhood — sometimes before the age of five, and in other cases during middle childhood or early adolescence. However, peanut allergy can also persist into adulthood. There is no universally predictable age at which resolution occurs, and each child's pattern of sensitisation is individual. Regular clinical review in an appropriate allergy service helps families understand whether reassessment may be appropriate over time.

What is the difference between peanut sensitisation and peanut allergy?

Sensitisation means that the immune system has produced IgE antibodies against a peanut protein. A positive specific IgE blood test or skin-prick test indicates sensitisation, but does not automatically mean the child will experience symptoms when eating peanut. Clinical allergy refers to a situation where exposure to peanut results in recognisable allergic symptoms. Some children are sensitised but do not react clinically — this distinction is important and requires careful clinical interpretation, ideally with specialist input.

Is a specific IgE blood test enough to confirm that a peanut allergy has resolved?

A specific IgE blood test can provide useful information and declining IgE levels may indicate a changing immune response, but a blood test alone is not sufficient to confirm that a peanut allergy has resolved. A supervised oral food challenge, where clinically appropriate, provides the most reliable indication of whether a child can safely tolerate peanut. IgE results should always be interpreted alongside the child's full clinical history.

Can a child with a peanut allergy safely eat other nuts?

Tree nuts and peanuts are biologically unrelated — peanuts are legumes, while tree nuts (such as almonds, cashews, walnuts and hazelnuts) are a separate food group. However, some children with peanut allergy are also allergic to one or more tree nuts, and some foods that contain tree nuts may also carry a risk of cross-contact with peanut. Whether a child with a peanut allergy can safely eat specific tree nuts depends on their individual clinical history and any relevant allergy assessment. This should be discussed with an appropriate healthcare professional.

What happens during a supervised oral food challenge for peanut?

A supervised oral food challenge involves the child consuming incrementally increasing amounts of peanut protein — typically starting with a very small dose — at timed intervals under direct observation by trained clinical staff. Vital signs and any symptoms are closely monitored throughout. The challenge is conducted in a setting with immediate access to emergency medication, including adrenaline. If any reaction occurs, it is treated promptly. The procedure is stopped if a significant reaction develops, and the result guides subsequent clinical decisions.

Should I stop my child's prescribed allergy medication before reassessment?

No. Do not stop, reduce or adjust any prescribed medication — including antihistamines, adrenaline auto-injectors or any other prescribed treatment — without explicit advice from your child's doctor or healthcare professional. Medication management around allergy reassessment requires clinical guidance. Your healthcare team will advise on any preparation that may be needed before specific tests.

Conclusion

Understanding whether a child has outgrown a peanut allergy is a medically nuanced question that cannot be answered by a single blood test or skin-prick test result alone. The clinical picture relies on a combination of metrics — including trends in allergen-specific IgE levels, skin-prick test findings, component-resolved diagnostic results, and ultimately a supervised oral food challenge where this is considered appropriate and safe.

For families managing a child's peanut allergy, regular review with an appropriate healthcare professional — whether through NHS allergy services, a GP referral or a private specialist setting — remains the most responsible approach. Whether any allergy testing is appropriate depends on the individual child's symptoms, medical history and clinical circumstances, and should always be considered as part of an appropriate healthcare assessment.

If you have specific concerns about your child's peanut allergy, or if you are wondering whether reassessment may be timely, the most appropriate first step is to discuss this with your GP or the healthcare professional responsible for your child's allergy management.

Disclaimer

This article is for general educational purposes only and does not replace personalised medical advice, diagnosis or treatment. If symptoms are severe, rapidly worsening, or suggest a serious allergic reaction, seek urgent medical attention. Online information and allergy testing should complement, not replace, an appropriate clinical assessment.

Written Date: 21 September 2026 Next Review Date: 21 September 2027